1. Jiuxing Feng†, *, Baitong Wu†, Yu Li, Pengli Sun, Qian Liu, Qianxue Xiao, Jia-Bin Cai, Yimin Zheng, Haonan Chen, Yichi Xu, Yixin Liu, Guo-Ming Shi, Li Tan, and Yujiang Geno Shi*. Tet2 deficiency–induced expansion of monocyte-derived macrophages promotes liver fibrosis. Journal of Experimental medicine, (2025). 10.1084/jem.20251114.

2.Baitong Wu, Jiuxing Feng†, Xi Wang, Jingyi Guo, Lanyue Sheng, Jian Wang, Jiaqi Xu, Jie Zhou, Guangming Wang, Yi Wen, Jiaxin Liu, Shu Zhao, Danjing Yang, Yinpeng Jin, Qingchun Fu, Jun Xu. miR-19b-3p Engineered Adipose-Derived Stem Cell Exosomes Attenuate Acute Liver Failure via Promoting Tissue Repair and Microenvironment Remodeling.Materials Today Bio (2025). 102697. doi.org/10.1016/j.mtbio.

3.Baitong Wu B, Jingyi Guo, Jian Wang, Jiuxing Feng*, Jun Xu. Adipose-derived stem cell extracellular vesicles attenuate liver fibrosis via restoration of gut barrier function and modulation of gut microbiota. Extracell Vesicles Circ Nucleic Acids. 2025;6:843-59.

4.Li S, Feng J†, Wu F, Cai J, Zhang X, Wang H, Fetahu IS, Iwanicki I, Ma D, Hu T, Liu H, Wang B, Shi G, Tan L, Shi YG. TET2 promotes anti-tumor immunity by governing G-MDSCs and CD8+ T-cell numbers. EMBO Reports. 2020 Oct 5;21(10):e49425.

5.Wu B, Feng J†, Guo J, Wang J, Xiu G, Xu J, Ning K, Ling B, Fu Q, Xu J. ADSCs-derived exosomes ameliorate hepatic fibrosis by suppressing stellate cell activation and remodeling hepatocellular glutamine synthetase-mediated glutamine and ammonia homeostasis. Stem Cell Research&Therapy. 2022 Oct 4;13(1):494.

6.Lyu Y, Lou J, Yang Y, Feng J†, Hao Y, Huang S, Yin L, Xu J, Huang D, Ma B, Zou D, Wang Y, Zhang Y, Zhang B, Chen P, Yu K, Lam EW, Wang X, Liu Q, Yan J, Jin B. Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways. Leukemia. 2017 Dec;31(12):2543-2551.

7.Feng J†, Chen S, Li S, Wu B, Lu J, Tan L, Li J, Song Y, Shi G, Shi YG, Jiang J. The association between monocytic myeloid-derived suppressor cells levels and the anti-tumor efficacy of anti-PD-1 therapy in NSCLC patients. Translational Oncology. 2020 Dec;13(12):100865.